Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT0101 phase I/IIa trial in advanced solid tumors and HER2-negative recurrent or metastatic breast cancer
jRCT2051240263Phase 1Recruiting
- Sponsor
- Periotherapia
- Start
- Mar 2025
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PT0101 and paclitaxel in Nonhematologic neoplasms and breast cancer, sponsored by Periotherapia. Primary endpoints: Adverse events and frequency, Dose-limiting toxicity and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
PT0101paclitaxel
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on jRCT2051240263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240263.